Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth With Ritlecitinib Through Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

    September 2023 in “ Journal of the American Academy of Dermatology ”
    Melissa Piliang, Charles Lynde, Brett King … Liza Takiya
    Studysummary This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Related research 7

    1. Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth With Ritlecitinib Through Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study Journal of the American Academy of Dermatology · 2023
    2. Scalp, Eyebrow, and Eyelash Hair Regrowth with Continued Ritlecitinib Treatment Among Patients with Alopecia Areata Without Target Efficacy Response at Week 24: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study Journal of the American Academy of Dermatology · 2023
    3. Baseline Distribution of Eyebrow and Eyelash Loss by Severity of Scalp Hair Loss in Phase 3 Trials of Baricitinib for Alopecia Areata Journal of The American Academy of Dermatology · 2023
    4. Concurrent Improvement in Scalp Hair and Eyebrow or Eyelash Regrowth in Patients With Severe Alopecia Areata Treated With Baricitinib Journal of The American Academy of Dermatology · 2023
    5. Scalp, Eyebrow, and Eyelash Hair Regrowth with Continued Ritlecitinib Treatment Among Patients with Alopecia Areata Without Target Efficacy Response at Week 24: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study SKIN The Journal of Cutaneous Medicine · 2023
    6. Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss Journal of The American Academy of Dermatology · 2022
    7. Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study Journal of The American Academy of Dermatology · 2021